An Observation Of The Impact On Danzhi Xiaoyao Powder And Remvastinib In The Therapy Of Advanced Primary Hepatocellular Carcinomas Of The Liver Depression And Spleen Deficiency Types

Objective:In this research,the clinical efficacy as well as safety of Danzhi Xiaoyao powder in combination with lovatinib for advanced primary hepatocellular carcinoma with liver depression as well as spleen deficiency type was evaluated.It provides clinical and practical guidance on combining Chinese and Western medicine for the therapy of advanced primary hepatocellular carcinomas with liver depressions and spleen deficiencies.Methods:Randomly dividing 54 patients sufferign from advanced hepatocellular cancer of the liver qi stagnation and spleen deficiency type into experimental and control cohorts.During the course of the trial,One patient in the experimental cohorts was rejected because of the combination of other drugs without the permission of medical staff,and one patient in the control cohorts was rejected because of the loss of contact,leaving 26 patients in every cohort.The experimental cohort was administered modified Danzhi Xiaotao powder;however,the control cohort was administered the targeted medication Remvastinib.Throughout the experiment,both cohorts of patients received symptomatic therapy,including nutritional assistance,liver protection,and stomach protection.Patients in both cohorts received therapy for 30 days per therapy course,for a total of 2 therapy courses.Two cohorts of patients were assessed before and following the therapy via TCM syndrome examination,short-term efficacy assessment,KPS value,liver function testing,alpha-fetoprotein testing,as well as safety assessment,as well as statistical analysis.Results:1.TCM syndrome value: There was a significant improvement in the TCM syndrome value of the 2 cohorts following therapy compared to that before therapy,with the test cohort outperforming the control cohort(P<0.05).Symptom values of the two cohorts showed a significant reduction in comparison to that of the control cohort following the therapy(P<0.05);however,the values of the symptoms of emaciation as well as dark complexion were not statistically significant(P>0.05).2.The effectiveness assessment index:The effectiveness assessment index: In the two cohort,overall response rates,disease control rates,and KPS values all with statistical differences(P<0.05).In the therapy cohort,overall response rates,disease control rates were 76.92 percent and 84.61 percent,respectively,and in the control cohort they were 53.85 percent and 61.54 percent.Alpha-fetoprotein(AFP): In the test and control cohorts,there was no statistically significant difference in AFP following the therapy(P>0.05).As compared with before therapy,AFP in the test cohort improved significantly following the therapy(P<0.05);in the control cohort,AFP improved significantly following the therapy(P<0.05).3.Safety assessment: There was a lower incidence of adverse events in the two cohorts compared with the control cohort in this study.There was a statistically significant difference among them in the incidence of hypertension as well as gastrointestinal upset(P<0.05),while there were no statistically significant differences in the incidence of rash or proteinuria(P>0.05).Conclusions:1.As a result of Dannhi Xiaoyao Powder and Remvastinib,patients suffering from primary hepatocellular carcinoma with liver depression and spleen deficiency can achieve an improved clinical outcome,enhance their quality of life,inhibit tumour cell growth,reduce tumour focus,and reduce liver damage.In comparison to ranvastinib alone,it has a better therapeutic effect.2.As a therapy for primary hepatocellular carcinoma accompanied by liver depression and spleen deficiency,modified Danzhi Xiaoyao Powder can alleviate the side effects of lovatinib,prevent the occurrence ofside effects of lovatinib,and enhance the tolerance for lovatinib among patients.